IMCAS Academy

Introduction
Program
Speakers
Sponsor list
Accreditation

IMCAS World Congress 2020
Program

FOCUS ON S152

Contributed talks - Cosmeceuticals & Nutraceuticals

Room: Room Passy - level 1
Date: Friday 31 January 2020 at 17:30 to 18:30
Format: CONTRIBUTED TALKS > session made up of abstract submissions that were carefully reviewed and selected by the Scientific Board

Chairs

Dr Victor Gabriel CLATICI

Dermatologist

Romania

Dr Heather WOOLERY LLOYD

Dermatologist

United States

Lectures of the session

Hours	Speakers	Lecture title	Abstract	Number
17:30	Dr Anastasia MASHKINA	Antihematomic preparation for injection procedures: how to minimize the risk of complications after traumatic procedures	View	98200
17:38	Byong Seung CHO	Stem cell-derived exosome and skin barrier	View	98202
17:46	Dr Alfred MARCHAL	Interest of tannic acid (TA) as a new cosmetic ingredient in anti-aging	View	96083
17:54	Dr Jeanine B DOWNIE	Cosmeceuticals and nutraceuticals as well as on filler complications.	View	85568
18:02	Dr Ricardo VILLA	Impact of carcinine supplementation on skin quality and correlation with metabolic parameter in metabolic syndrome	View	96427
18:10	Dr Dinko KALITERNA	Do we need the lasers for melasma removal?	View	100014
18:18	Dr Juliane ROCIO NEVES	Clinical efficacy of a topical serum containing 15% L-Ascorbic acid, neohesperidin, pycnogenol, tocopherol and HA on the skin aging signs	View	100067
18:26		Q&A		100403

Go to previous session

Go to next room (Room 153 - level 1)

Recommended sessions

Cosmeceuticals

Skin aging

Antioxidants

Photoaging

Fillers: HA (hyaluronic acid)

Dr Anastasia MASHKINA

Dermatologist

Russia

Other author(s) :

Antihematomic preparation for injection procedures: how to minimize the risk of complications after traumatic procedures

Objectives: The aim of this study was to develop recommendations that shorten the recovery period after invasive procedures and reduce the risk of post-traumatic infection of soft tissues.

Introduction: The rhythm of modern life dictates the conditions under which the employee cannot fall out of the schedule for a long time. In this regard, there is an acute question of reducing the time for rehabilitation and prevention of complications after injection anti-aging procedures.

Materials / method: The study involved 20 volunteers who were shown contouring and thread lifting procedures associated with a high risk of hematomas in the post-treatment period. They received anti-hematoma therapy, including taking anti-hematoma drugs inside, as well as using external forms 5 days before the procedure, on the day of the procedure, and 2 days after the procedure. The control group consisted of 20 patients receiving the same procedures, but without anti-hematoma therapy.

Results: When comparing the course of the rehabilitation period, it was found that after anti-hematoma prophylaxis, the rehabilitation period was reduced by an average of 3 to 4 days, the size of the hematomas was much smaller and faster than in the control group.

Conclusion: Accordingly, it can be concluded that the anti-hematoma therapy has a beneficial effect on the post-treatment period, and reduces the risk of post-traumatic infection and other complications.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Byong Seung CHO

Industry Representative

South Korea

Other author(s) : Byong Cho

Stem cell-derived exosome and skin barrier

Objectives: 1. To know that stem cell-derived exosomes can be used as next generation regenerative aesthetics and therapeutics
2. To know that stem cell-derived exosomes can reconstruct skin barrier functions and be a new therapeutic candidate for atopic dermatitis (AD)
3. To know that stem cell-derived exosomes are safe for skin

Introduction: Exosomes, nano-sized extracellular vesicles, are the most important mediator for intercellular communication. These days, stem cell-derived exosomes are being developed as cosmetics/cosmeceuticals and therapeutics as well. It was found that stem cell-derived exosomes can be very effective for skin rejuvenation/regeneration and atopic dermatitis through reconstitution of skin barrier functions. It was also found that stem cell-derived exosomes showed safe toxicological profiles.

Materials / method: Human adipose tissue-derived mesenchymal stem cell-derived exosomes (ASC-Exosomes) were used for in vitro, ex-vivo, and in vivo studies.

Results: ASC-Exosomes:
1. contain active cargo: >1,000 proteins & ~600 miRNAs. Many of them are functional for skin;
2. effective for skin rejuvenation: increased collagen & elastin synthesis;
3. effective for atopic dermatitis in an inflammatory model: reduced clinical score, IgE level, cytokine mRNAs, & inflammatory cells;
4. effective for atopic dermatitis in a skin barrier model: reduced TEWL, epithermal thickness, & cytokines; increased the lipids; normalized gene expression for skin barrier, lipid metabolism, cell cycle, & immune response; &
5. safe for skin: no toxicity in toxicology evaluation.

Conclusion: 1. ASC-exosomes can be a novel anti-aging product for next generation regenerative aesthetics, which is superior to conventional skin boosters.
2. ASC-exosomes can be a novel promising cell-free therapeutic modality for AD treatment.
3. ASC-exosomes can be applied on skin with no significant toxicity.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): ExoCoBio Inc.

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): ExoCoBio Inc.

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): ExoCoBio Inc.

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
Yes
Please specify date...: Patented
and status : July 2017

This work is presented thanks to the support of: ExoCoBio Inc.

Dr Alfred MARCHAL

PhD - Research

Belgium

Other author(s) : Alfred MARCHAL

Interest of tannic acid (TA) as a new cosmetic ingredient in anti-aging

Objectives: Tannic Acid (TA) has the following properties for treating:
Bruises and redness
Anti pigmentation and redness
Antipollution
Anti aging
Free radical protection and scavengers
Vasoprotection
Regulation of pigmentation
Antipollution agent

Introduction: TA presents a clear innovation as cosmetic ingredient for anti ageing products and dermatology. Because of the difficulties to formulate TA and its poor stability it was never commercialised before because TA is completely instable and present great difficulties to formulate.

Materials / method: TA is coming form plants and is concentrated in Sequoia tress bark. The extract containing the purified molecule is a light brown powder purified at 90 %
The molecule posses a very great number of hydroxyl groups which brings its intense original polyphenol activity.

Results: Studies will show the results of the activity of TA works as, iron ions chelator, strong antioxidant, H2O2 scavenger, superoxide anion radical scavenging , anti glycation and it presents also effects on the endothelium of blood vessels and some application in post cancer treatment side effects.

Conclusion: As conclusion we can assume the following:
Protection of free radicals activities
Anti microbial and anti fungal actionBlocks ROS activation
Chelation of PM
Free radicals scavenger
Protect as strong antioxidant
Block ageing and skin degradation process

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Jeanine B DOWNIE

Dermatologist

United States

Other author(s) : Jenaine Downie, MD

Cosmeceuticals and nutraceuticals as well as on filler complications.

Objectives: I would like to update fellow doctors on the latest Cosmeceuticals and Nutraceuticals available for them to recommend out of their offices. I will review all updated technology and discuss return on investment from selling products in your office.

Introduction: Professional skin care industry as a whole is 11 Billion Dollars
Only 500 Million dollars is spent in the physician dispensed channel
As a comparison, $2 Billion is spent Sephora
71% of women will try a new skin care products each moth because they are not happy with their current products (most have a wrinkle cream graveyard in their cabinet/ bathroom)
76% of patients want to be asked about skincare
75% of patients will purchase if the doctor/PA makes recommendation

Materials / method: none

Results: Physicians listening to this lecture should be able to increase their knowledge on what the available Cosmeceuticals and Nutraceuticals options are so that they can increase their product revenue.

Conclusion: Physicians listening to this lecture should be able to increase their knowledge on what the available Cosmeceuticals and Nutraceuticals options are so that they can increase their product revenue.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Ricardo VILLA

Dermatologist

Brazil

Other author(s) : Authors: Simas, L.A.W.; Granzoti, R. O.; Novak, B; Wolpe, R.E.; Zilbert, B.; Villa, R.T.+; Yamaguchi E.M. ++; Brederodes Villa, A.C.F.B.B. + +UFMA ++UNIFESP

Impact of carcinine supplementation on skin quality and correlation with metabolic parameter in metabolic syndrome

Objectives: Objective: we hypothesized that carcinine would improve skin quality, glycemic control, insulin resistance and lipid profile in overweight and obese patients.

Introduction: Introduction: carcinine is a dipeptide found in mammalian tissues (SONG et al., 2014). Studies have demonstrated its anti-inflammatory, anti-glycant and antioxidant activity by different mechanisms (Hinkley et al., 2007) and it could be used in the treatment of metabolic syndrome (MS) (Anderson et al., 2018). On the other hand, aging process shares aspects of MS pathophysiology and could be treated with carcinine (Babizhayev 2011), although there is no study evaluating both skin and MS simutaneously.

Materials / method: Materials and Methods: female patients, aged between 40 and 60 years, body mass index between 25 and 34.9 (kg / m2) were eligible to participate in a randomized, double-blind, placebo-controlled clinical trial. 38 patients were recruited and assigned to intervention group (n = 19, receiving 1 capsule of 20 mg of carcinine daily) or control (n = 19). Photographs were taken and samples of blood and anthropometry were collected at baseline, after 45 and 90 days. A photo analysis software was used to evaluate wrinkles, erythema and pigmentation. Statistical analysis was performed using two-way ANO

Results: Results: after 90 days, carcinine supplementation resulted in a significant decrease in wrinkles, spots, and texture (p<0.005), paralled by reduction of fasting glycemia (p = 0.001), fructosemia (p = <0.001) glycated hemoglobin (p = 0.003), cholesterol (p = 0.004), insulin (p = 0.038), abdominal circumference (p = 0.013) and HOMA-IR (p = 0.039).

Conclusion: Conclusions: the parameters investigated showed a significant improvement after 90 days of supplementation. Additionally, beyond its own results, this study reinforces the need to treat the patient as a whole, since improving their clinical conditions (e.g., MS) has a positive impact on all tissues, including skin.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Dinko KALITERNA

Dermatologist

Croatia

Other author(s) :

Do we need the lasers for melasma removal?

Objectives: Melasma is not only hyperpigmentation disorder. VEGF is increased at the places of the hyperpigmentation. If we want successfully remove melasma we need to destroy capillaries.

Introduction: Melasma is a very common aesthetic problem which is sometimes very challenging not only for the doctor but also for the client. There are many causes of melasma. Besides UV rays, the visible light also plays a very important role with the mast cells, keratinocytes, suprarenal hormones and VEGF.

Materials / method: Until recently the laser was the only solution for that. Today pico lasers represent one of the most effective treatments for the melasma removal. There are many effective ingredients to remove melasma. We need to use the ingredients which affect the capillaries like tranexamic acid.

Results: We want to represent such cream which represents a big breakthrough for the melasma removal because it gives very often the result which is comparable or better than a laser.

Conclusion: The main limit of the previous cream for the melasma removal was that they did not affect the capillaries. Thanks to this creams the lasers don t play any more the main role for the melasma removal.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Juliane ROCIO NEVES

Dermatologist

Brazil

Other author(s) : Juliane Rocio Neves, Paula Zambelli, Beatriz Sant'Anna, Delphine Kerob

Clinical efficacy of a topical serum containing 15% L-Ascorbic acid, neohesperidin, pycnogenol, tocopherol and HA on the skin aging signs

Objectives: Evaluating the efficacy of a topical potent antioxidant serum containing 15% L-Ascorbic Acid, Neohesperidin, Pycnogenol, tocopherol and Hyaluronic Acid in skin ageing signs of Brazilian subjects with clinical, instrumental and skin imaging assessment techniques

Introduction: Skin Aging is a process linked to chronological aging and exposome such aschronic UV exposure and pollution which both induce, among other effect, reactive oxygen species. Therefore, topical formulations which have strong antioxidant effect could counteract this process. The current formulation combines strong antioxidant ingredients such as 15% of L-Ascorbic Acid, Neohesperidin, Pycnogenol, tocopherol with fragmented Hyaluronic Acid to improve the extracellular matrix.

Materials / method: 40 female subjects 40 to 65 years old, with phototype II to IV, presenting wrinkles (frontal, glabellar and naslolabial folds) score ≥ 2 to 5 (from Skin Aging Atlas), and facial dark spots (excluding ephelides and melasma) and/or lentigo were included in the study. All of them were evaluated for clinical efficacy and safety. 20 of them underwent instrumental (Primos, Visia CR, Cutometer, Chroma Meter) and 16 skin imaging (Confocal). The evaluation were performed after 45 and 90 days of product use. The confidence interval considered in the comparative analysis between time-points was of 95%.

Results: A statistically significant improvement on skin ageing signs were observed at day 90: frontal, nasolabial and glabellar wrinkles improved by 23.9%, 22.7% and 19.1%. Similar results were observed for skin tone homogeneity, dark spots color intensity and hyperpigmentation which were confirmed by VISIA. Instrumental measures at day 90 demonstrated improvements of skin texture, depth and volume of wrinkles; skin firmness and elasticity; skin homogeneity; in thickness of the epidermis and of the stratum corneum; and the morphology of the dermis and stratum corneum. No adverse events were observed.

Conclusion: The topical potent antioxidant serum containing 15% L-Ascorbic Acid, Neohesperidin, Pycnogenol, tocopherol and Hyaluronic Acid demonstrated a clinically relevant efficacy on skin ageing conditions, with a good safety profile after 90 days of daily use.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): VICHY, L’Oreal, Paris, France.

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): VICHY, L’Oreal, Paris, France.

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: VICHY, L’Oreal, Paris, France.

Q&A

You have a question?

Quickly find your answer in our FAQ

Congresses

IMCAS Americas
IMCAS Asia
IMCAS World Congress

About

Company
Privacy Policy
Legal information

Academy

Home
Courses
Webinars
Explore
Blog

Grant

Educational grant

Get in touch

Username/Email

Password

Keep me logged in

Forgot password ? Do not have an account yet? Sign up now

Keep me logged in

academy.Do_not_have_an_account_yet Sign up now

IMCAS World Congress 2020 Program

FOCUS ON S152

Contributed talks - Cosmeceuticals & Nutraceuticals

Chairs

Lectures of the session

Recommended sessions

IMCAS World Congress 2020
Program